Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Liquid Biopsies 2019

Bernhard Zimmermann's Biography

Bernhard Zimmermann, Vice President of Research and Development, Natera

Bernhard Zimmermann has been a pioneer in the field of cell-free DNA for 20 years. At Natera he was the lead scientist in the development of massively multiplex PCR and the market-leading Panorama non-invasive prenatal test (NIPT). More recently, his team has developed multiple workflows for analysis of circulating tumor DNA using fixed and personalized panels. Results of this work were published in a cover article of Nature with the title “Phylogenetic ctDNA analysis depicts early stage lung cancer evolution”. In August 2017 Natera launched the personalized Liquid Biopsy test, Signatera, for research use only.

Bernhard Zimmermann Image

Monitoring Recurrence With Personalized ctDNA Assays

Wednesday, 27 March 2019 at 16:30

Add to Calendar ▼2019-03-27 16:30:002019-03-27 17:30:00Europe/LondonMonitoring Recurrence With Personalized ctDNA AssaysLiquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island,

Signatera™ RUO is the first individualized pan-cancer circulating tumor DNA platform. I will be showing results of validation studies for monitoring treatment response, detecting minimal residual disease and predicting disease recurrence. The test detects tumor DNA down to 0.01% VAF (tumor fraction) and data from clinical studies in lung cancer, bladder cancer, colorectal cancer and breast cancer show that ctDNA is detected in plasma of patients up to over one year ahead of clinical detection of relapse.

Add to Calendar ▼2019-03-27 00:00:002019-03-29 00:00:00Europe/LondonLiquid Biopsies 2019Liquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island,